Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis
Excerpt from the Press Release:
SAN FRANCISCO–(BUSINESS WIRE)–Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development.
The compounds work in a new way: instead of interfering with the virus’s own functions, as do traditional antiviral drugs, this approach targets a newly appreciated structure within human cells that is hijacked and altered by viruses when they infect the cell, as part of their replication process.
A large body of work suggests that to be successful a virus must not only reconfigure and redirect host cell machinery needed for its replication, but must also block the fundamental host defense termed innate immunity. Novel biochemical readouts of both of these viral actions have been established by the Prosetta team, and the new drugs shown to oppose the virus on both fronts.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?